Results 61 to 70 of about 5,805 (230)
Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model
Molecular Oncology, EarlyView.Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker +19 morewiley +1 more sourceInhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Molecular Oncology, EarlyView.Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder +11 morewiley +1 more sourceMET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer
Molecular Oncology, EarlyView.Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song +11 morewiley +1 more sourceThe TESS-Keck Survey. XVII. Precise Mass Measurements in a Young, High-multiplicity Transiting Planet System Using Radial Velocities and Transit Timing Variations
The Astronomical JournalWe present a radial velocity (RV) analysis of TOI-1136, a bright Transiting Exoplanet Survey Satellite (TESS) system with six confirmed transiting planets, and a seventh single-transiting planet candidate.Corey Beard, Paul Robertson, Fei Dai, Rae Holcomb, Jack Lubin, Joseph M. Akana Murphy, Natalie M. Batalha, Sarah Blunt, Ian Crossfield, Courtney Dressing, Benjamin Fulton, Andrew W. Howard, Dan Huber, Howard Isaacson, Stephen R. Kane, Grzegorz Nowak, Erik A Petigura, Arpita Roy, Ryan A. Rubenzahl, Lauren M. Weiss, Rafael Barrena, Aida Behmard, Casey L. Brinkman, Ilaria Carleo, Ashley Chontos, Paul A. Dalba, Tara Fetherolf, Steven Giacalone, Michelle L. Hill, Kiyoe Kawauchi, Judith Korth, Rafael Luque, Mason G. MacDougall, Andrew W. Mayo, Teo Močnik, Giuseppe Morello, Felipe Murgas, Jaume Orell-Miquel, Enric Palle, Alex S. Polanski, Malena Rice, Nicholas Scarsdale, Dakotah Tyler, Judah Van Zandt +43 moredoaj +1 more sourceChemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation
Molecular Oncology, EarlyView.This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam +14 morewiley +1 more sourceA Fourth Planet in the Kepler-51 System Revealed by Transit Timing Variations
The Astronomical JournalKepler-51 is a ≲1 Gyr old Sun-like star hosting three transiting planets with radii ≈6–9 R _⊕ and orbital periods ≈45–130 days. Transit timing variations (TTVs) measured with past Kepler and Hubble Space Telescope (HST) observations have been ...Kento Masuda, Jessica E. Libby-Roberts, John H. Livingston, Kevin B. Stevenson, Peter Gao, Shreyas Vissapragada, Guangwei Fu, Te Han, Michael Greklek-McKeon, Suvrath Mahadevan, Eric Agol, Aaron Bello-Arufe, Zachory Berta-Thompson, Caleb I. Cañas, Yayaati Chachan, Leslie Hebb, Renyu Hu, Yui Kawashima, Heather A. Knutson, Caroline V. Morley, Catriona A. Murray, Kazumasa Ohno, Armen Tokadjian, Xi Zhang, Luis Welbanks, Matthew C. Nixon, Richard Freedman, Norio Narita, Akihiko Fukui, Jerome P. de Leon, Mayuko Mori, Enric Palle, Felipe Murgas, Hannu Parviainen, Emma Esparza-Borges, Daniel Jontof-Hutter, Karen A. Collins, Paul Benni, Khalid Barkaoui, Francisco J. Pozuelos, Michaël Gillon, Emmanuël Jehin, Zouhair Benkhaldoun, Suzanne Hawley, Andrea S. J. Lin, Guđmundur Stefánsson, Allyson Bieryla, Mesut Yilmaz, Hakan Volkan Senavci, Eric Girardin, Giuseppe Marino, Gavin Wang +51 moredoaj +1 more sourceTonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes +17 morewiley +1 more sourceGiant Outer Transiting Exoplanet Mass (GOT ‘EM) Survey. IV. Long-term Doppler Spectroscopy for 11 Stars Thought to Host Cool Giant Exoplanets
The Astrophysical Journal Supplement SeriesDiscovering and characterizing exoplanets at the outer edge of the transit method’s sensitivity has proven challenging owing to geometric biases and the practical difficulties associated with acquiring long observational baselines.Paul A. Dalba, Stephen R. Kane, Howard Isaacson, Benjamin Fulton, Andrew W. Howard, Edward W. Schwieterman, Daniel P. Thorngren, Jonathan Fortney, Noah Vowell, Corey Beard, Sarah Blunt, Casey L. Brinkman, Ashley Chontos, Fei Dai, Steven Giacalone, Michelle L. Hill, Molly Kosiarek, Jack Lubin, Andrew W. Mayo, Teo Močnik, Joseph M. Akana Murphy, Erik A. Petigura, Malena Rice, Ryan A. Rubenzahl, Judah Van Zandt, Lauren M. Weiss, Diana Dragomir, David Kipping, Matthew J. Payne, Arpita Roy, Alex Teachey, Steven Villanueva Jr. +31 moredoaj +1 more sourceAberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu +12 morewiley +1 more source
